Skip to main content
. 2017 Jun 12;16(2):1340–1346. doi: 10.3892/mmr.2017.6754

Figure 3.

Figure 3.

TFPS inhibits pro-apoptotic pathways and activates pro-survival pathways in human skin fibroblasts. (A-I) p16, p21, Bax, p53, SIRT1, Caspase-3, p-Akt, Akt, p-ERK, ERK and GAPDH protein expression in control, H2O2-treated (300 µM), H2O2-treated, TFPS pretreated (200 µg/ml), and TFPS (200 µg/ml) pretreated in skin fibroblasts as assayed by western blotting (n=4, *P<0.05, **P<0.01, and ***P<0.001 vs. control; #P<0.05, ##P<0.01 vs. H2O2 group). (J and K) SIRT1 and GAPDH protein expression in the presence of 0–500 µM H2O2 for 24 h, as assayed by western blotting (n=3, *P<0.05, **P<0.01, ***P<0.001 vs. control). (L and M) SIRT1 and GAPDH protein expression with and without 0–300 µg/ml TFPS pre-treatment for 1 h and then application of 300 µM H2O2 for 24 h, as assayed by Western blotting (n=4, *P<0.05 and ***P<0.001 vs. control; #P<0.05 vs. 300 µM H2O2 group).